Marie De Antonio

Marie De Antonio

Auto-generated profile, based on publicly available information

Marie De Antonio

CHU Clermont-Ferrand, Biostatistics Unit, Clermont-Ferrand, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Revue Neurologique
Verified
Journal Article
Closed access
MAM De Antonio
M De Antonio
CDC Dogan
C Dogan
Hamroun DalilHamroun Dalil
Hamroun Dalil
MMM Mati
M Mati
SZS Zerrouki
S Zerrouki
FNFrench Myotonic Dystrophy Clinical Network
French Myotonic Dystrophy Clinical Network

5 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CDCeline Dogan
Celine Dogan
MAMarie De Antonio
Marie De Antonio
Hamroun DalilHamroun Dalil
Hamroun Dalil
HVHugo Varet
Hugo Varet
MFMarianne Fabbro
Marianne Fabbro
GBGuillaume Bassez
Guillaume Bassez
Myotonic Dystrophy type 1 (DM1) is one of the most heterogeneous hereditary disease in terms of age of onset, clinical manifestations, and severity, challenging both medical management and clinical trials. The CTG expansion size is the main factor determining the age of onset although no factor can finely predict phenotype and prognosis. Differences between males and females have not been specifically reported. Our aim is to study gender impact on DM1 phenotype and severity. We first performed cross-sectional analysis of main multiorgan clinical parameters in 1409 adult DM1 patients (>18y) from the DM-Scope nationwide registry and observed different patterns in males and females. Then, we assessed gender impact on social and economic domains using the AFM-Téléthon DM1 survey (n = 970), and morbidity and mortality using the French National Health Service Database (n = 3301). Men more frequently had (1) severe muscular disability with marked myotonia, muscle weakness, cardiac, and respiratory involvement; (2) developmental abnormalities with facial dysmorphism and cognitive impairment inferred from low educational levels and work in specialized environments; and (3) lonely life. Alternatively, women more frequently had cataracts, dysphagia, digestive tract dysfunction, incontinence, thyroid disorder and obesity. Most differences were out of proportion to those observed in the general population. Compared to women, males were more affected in their social and economic life. In addition, they were more frequently hospitalized for cardiac problems, and had a higher mortality rate. Gender is a previously unrecognized factor influencing DM1 clinical profile and severity of the disease, with worse socio-economic consequences of the disease and higher morbidity and mortality in males. Gender should be considered in the design of both stratified medical management and clinical trials.

23 October 2014 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
JAJessie Aouizerate
Jessie Aouizerate
MAMarie De Antonio
Marie De Antonio
GBGuillaume Bassez
Guillaume Bassez
RGRomain K Gherardi
Romain K Gherardi
FBFrancis Berenbaum
Francis Berenbaum
FAFrançois Jérôme Authier
François Jérôme Authier
To assess the value of major histocompatibility complex (MHC) class II antigen (HLA-DR) expression to distinguish anti-synthetase myopathy (ASM) from dermatomyositis (DM). Muscle biopsies from patients with ASM (n = 33), DM without anti-synthetase antibodies (ASAb) (n = 17), and normal muscle biopsy (n = 10) were first reviewed. ASAb included anti-Jo1 (26/33), anti-PL12 (4/33), anti-PL7 (2/33), and anti-EJ (1/33). Immunohistochemistry was performed for MHC-I/HLA-ABC, MHC-II/HLA-DR, membrane attack complex (C5b-9), neural cell adhesion molecule (NCAM)/CD56 expression, and inflammatory cell subsets. Twenty-four ASM and 12 DM patients from another center were added for HLA-DR evaluation. Ubiquitous myofiber HLA-ABC expression was equally observed in ASM and DM (93.9% vs 100%, NS). In contrast, myofiber HLA-DR expression was found in 27/33 (81.8%) ASM (anti-Jo1: 23/26, 88.5%; others: 5/7, 71.4%) vs 4/17 (23.5%) DM patients (p < 0.001). HLA-DR was perifascicular in ASM, a pattern not observed in DM. In addition, C5b-9 deposition was observed on sarcolemma of non-necrotic perifascicular fibers in ASM, while, in DM, C5b-9was mainly detected in endomysial capillaries. CD8 cells were more abundant in ASM than in DM (p < 0.05), and electively located in perimysium or in perifascular endomysium. HLA-DR expression correlated positively with the CD8+ cells infiltrates. Strictly similar observations were made in the confirmatory study. ASM is characterized by strong myofiber MHC-II/HLA-DR expression with a unique perifascicular pattern, not described so far. HLA-DR detection must be included for routine myopathological diagnosis of inflammatory/dysimmune myopathies. HLA-DR expression in ASM may indicate a specific immune mechanism, possibly involving IFNγ.

7 April 2016 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
YDYohann Dabi
Yohann Dabi
LDLauren Darrigues
Lauren Darrigues
SKSandrine Katsahian
Sandrine Katsahian
DADaniel Azoulay
Daniel Azoulay
MAMarie De Antonio
Marie De Antonio
ALAndrea Lazzati
Andrea Lazzati

30 September 2015 in Rheumatology
Verified
Journal Article
Closed access
PDF file
CGCyril Gitiaux
Cyril Gitiaux
MAMarie De Antonio
Marie De Antonio
JAJessie Aouizerate
Jessie Aouizerate
RGRomain K. Gherardi
Romain K. Gherardi
TGThomas Guilbert
Thomas Guilbert
BBBrigitte Bader-Meunier
Brigitte Bader-Meunier
Objective. Outcome of JDM is highly heterogeneous. Our objective was to determine clinical and muscle biopsy features associated with poor outcome and response to treatment.

4 November 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EMElisa Masat
Elisa Masat
PLPascal Laforêt
Pascal Laforêt
MAMarie De Antonio
Marie De Antonio
GCGuillaume Corre
Guillaume Corre
BPBarbara Perniconi
Barbara Perniconi
FGFrench Pompe Registry Study Group
French Pompe Registry Study Group
Immunogenicity of recombinant human acid-alpha glucosidase (rhGAA) in enzyme replacement therapy (ERT) is a safety and efficacy concern in the management of late-onset Pompe disease (LOPD). However, long-term effects of ERT on humoral and cellular responses to rhGAA are still poorly understood. To better understand the impact of immunogenicity of rhGAA on the efficacy of ERT, clinical data and blood samples from LOPD patients undergoing ERT for >4 years (n = 28) or untreated (n = 10) were collected and analyzed. In treated LOPD patients, anti-rhGAA antibodies peaked within the first 1000 days of ERT, while long-term exposure to rhGAA resulted in clearance of antibodies with residual production of non-neutralizing IgG. Analysis of T cell responses to rhGAA showed detectable T cell reactivity only after in vitro restimulation. Upregulation of several cytokines and chemokines was detectable in both treated and untreated LOPD subjects, while IL2 secretion was detectable only in subjects who received ERT. These results indicate that long-term ERT in LOPD patients results in a decrease in antibody titers and residual production of non-inhibitory IgGs. Immune responses to GAA following long-term ERT do not seem to affect efficacy of ERT and are consistent with an immunomodulatory effect possibly mediated by regulatory T cells.